GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

QuantumRD demonstration to Chevron

14 Mar 2012 07:00

RNS Number : 2422Z
ViaLogy PLC
14 March 2012
 



 

 

ViaLogy PLC ("ViaLogy" or "the Company")

 

ViaLogy Delivers Novel Technology to Chevron

 

London, March 14, 2012. ViaLogy PLC (VIY) announces it has completed a key demonstration project of its QuantumRD technology under contract with Chevron U.S.A. Inc. Working closely with Chevron geophysicists, ViaLogy successfully applied QuantumRD to a 3D seismic data set for the purpose of delineating the porosity trends in the tight dolomites of the lower Permian Basin.

 

Variations in carbonates with low porosity have extremely small expression in the seismic response buried below background noise in the data and previous attempts to discriminate had not been successful. The QuantumRD workflow processes events down to signal amplitudes below -24dB to assess how coherent and random noise within the full seismic acquisition spectrum is differentially and directly modulated by subtle changes in porosity. Unlike conventional signal processing, QuantumRD uses a synthetic noise source, designed using rock-physics and well-control data to probe the acquired seismic data and to detect, characterize and amplify changes in seismic noise. This process of excitation of conventionally acquired seismic data using synthetic noise in software, determines attributes of interest, such as presence of pre-specified levels of porosity, as emergent quantum resonances. In less technical terms, ViaLogy points out that QuantumRD was able to discern porosity, a key rock property in locating and identifying hydrocarbon deposits, where other techniques have not. The significance of this is that it could bring a new level of accuracy and predictive capability to hydrocarbon reservoir characterization.

 

Sandeep Gulati, ViaLogy's VP for Product Development and CTO, states "QuantumRD produced an attribute for predicting porosity 2 to 3 miles away from existing wells, something considered extremely difficult for this type of formation. Such predictions at the vertical intervals used represent a twofold increase over conventional seismic interpretation resolution. One project conclusion is that utilizing this method could result in significant reduction of the wells actually needed to extract oil over current standard gridding techniques, while increasing recovery from optimally placed wells based on QuantumRD analysis."

 

ViaLogy's CEO Robert Dean commented, "Putting our technology to use on behalf of another of the world's leading oil companies has given ViaLogy the opportunity to show that it could solve some of the key extraction problems facing the industry today, and that it holds the promise of helping E&P firms avoid risks and saving considerable capital expenditure costs, and -in an era of increasing demand for gas and oil - could serve as a valuable tool for further and more efficient production from fields that have thus far proven to be uneconomic. We look forward to continuing our work with Chevron under our existing contract with them."

 

For further information contact: 

ViaLogy Plc

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 20-7107-8000

Katie Ratner, Corporate Broking +44 (0) 20-7107-8000

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery. ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBXLFFLXFEBBQ
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.